Global Neurological Biomarkers Market Trends and Growth Analysis 2025–2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Does The Market Size Of The Neurological Biomarkers Industry Compare Between 2025 And 2029?

The market for neurological biomarkers has experienced rapid expansion in recent years. Its value is projected to rise from $10.7 billion in 2024 to $11.92 billion in 2025, reflecting a compound annual growth rate (CAGR) of 11.4%. This historical growth can be attributed to several factors including the increasing prevalence of neurological disorders, an aging population, the demands of drug development, greater funding for neurological research, and the emergence of personalized medicine.

The neurological biomarkers market size is projected to experience substantial expansion in the coming years. This market is set to reach $19.91 billion by 2029, achieving a compound annual growth rate (CAGR) of 13.7%. Driving this expansion during the projected timeframe are key elements such as biomarkers for early detection, biosensors, wearable devices, global health initiatives, and a patient-centric approach. Significant developments expected in the forecast period encompass technological innovation in imaging, rapid advances in omics technologies, the integration of artificial intelligence (AI), the use of real-world evidence in biomarker validation, advancements in diagnostic technologies, and increased collaboration between industry and research institutions.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12677&type=smp

What Are The Drivers Pushing New Developments In The Neurological Biomarkers Market?

The expanding occurrence of neurological diseases is projected to drive the expansion of the neurological biomarker market in the future. These conditions impact the brain, spinal cord, and the entire nervous system throughout the body. Parkinson’s disease, a neurodegenerative condition, affects the neurological system and parts of the body controlled by nerves. Neurological biomarkers facilitate the early detection of Parkinson’s disease through pathological, biochemical, and genetic assessments. For example, in December 2022, the Parkinson’s Foundation, a US-based non-profit organization, reported that new Parkinson’s disease diagnoses reached 90,000 in 2022, an increase from 60,000 annually in 2021. Consequently, the rising incidence of neurological diseases is fueling the growth of the neurological biomarker market.

What Are The Major Segment Types Covered In The Neurological Biomarkers Market?

The neurological biomarkersmarket covered in this report is segmented –

1) By Product: Proteomics Biomarker; Genomics Biomarker; Metabolomics Biomarker; Imaging Biomarker; Other Products

2) By Application: Alzheimer’s Disease; Parkinson’s Disease; Huntington’s Disease; Schizophrenia; Depression; Multiple Sclerosis; Spinal Muscular Atrophy

3) By End-User: Hospital Laboratories; Clinical Diagnostic Centers; Research Organizations; Other End-Users

Subsegments:

1) By Proteomics Biomarker: Protein Biomarkers; Antibody Biomarkers

2) By Genomics Biomarker: DNA Biomarkers; RNA Biomarkers

3) By Metabolomics Biomarker: Metabolite Biomarkers; Lipid Biomarkers

4) By Imaging Biomarker: MRI Biomarkers; PET Scan Biomarkers

5) By Other Products: Neuroinflammatory Biomarkers; Neurotransmitter Biomarkers

How Are Emerging Market Trends Shaping The Neurological Biomarkers Industry Landscape?

Leading firms in the neurological biomarkers market are establishing alliances to create novel products and fortify their market presence. These alliances within the neurological biomarkers market promote innovation, utilize diverse expertise, and hasten the creation and market launch of cutting-edge therapies through shared resources and abilities. An example is the partnership formed in July 2022 between NeuroSense Therapeutics Ltd., an Israel-based firm focused on treatments for severe neurodegenerative diseases, and NeuraLight, also Israel-based, which specializes in developing objective and sensitive biomarkers for neurological conditions. The goal of this collaboration is to pinpoint oculometric indicators for Amyotrophic Lateral Sclerosis (ALS) by employing Artificial Intelligence (AI) and Machine Learning (ML) technologies. Following NeuraLight’s $25 million Series A financing, this partnership aims to advance the identification and utilization of ALS digital indicators within a concurrent study. This marks the inaugural clinical trial for their collaborative efforts. The core of this alliance lies in applying oculometric digital indicators, potentially enabling better patient categorization and improving the success rates of clinical trials.

Which Major Industry Participants Are Leading The Neurological Biomarkers Market Growth?

Major companies operating in the neurological biomarkers market include Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Thermos Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories, Boehringer Ingelheim International GmbH, Becton Dickinson and Company, Agilent Technologies Inc., Grifols S.A., Eisai Co. Ltd., PerkinElmer Inc., Illumina Inc., Shimadzu Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Mallinckrodt Plc, Qiagen N.V., Luminex Corporation, Siemens Healthineers, Olink Proteomics, Meso Scale Diagnostics, Quanterix Corp., Fujirebio, Cisbio Bioassays SAS, NeuroVision Imaging, Proteome Sciences Plc, Acumen Pharmaceuticals.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report

Which Regional Markets Are Contributing Most To The Neurological Biomarkers Industry Expansion?

North America was the largest region in the neurological biomarkers market in 2024. The regions covered in the neurological biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Neurological Biomarkers Market Report:

https://www.thebusinessresearchcompany.com/customise?id=12677&type=smp

Browse Through More Reports Similar to the Global Neurological Biomarkers Market 2025, By The Business Research Company

Biomarkers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Rare Neurological Disease Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Neurology Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neurology-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795